Driving innovation in the AI-enabled Alzheimer’s and dementia treatment with a commitment to transforming personalized healthcare
Alzheimer’s Treatment Centers of America (ATCA) announces that Dr. Mark Rosenbloom has joined the Advisory Board of Alzheimer's Treatment Centers of America.
“Dr. Mark Rosenbloom brings decades of experience in root cause analysis
as it relates to longevity which also has positive implications for our
Alzheimer’s disease and dementia patients,” said Greg Buckley,
CEO of Alzheimer’s Treatment Centers of America. “Mark can suggest even
more incredible tools to add value to ATCA’s treatment protocols.”
“I am all about anti-aging and performance when it comes to medicine,”
adds Dr. Mark Rosenbloom. “When I founded LifeForce, I knew I was
involved with precision medicine that has now become my purpose and my
passion. When my parents suffered from Alzheimer’s in their later years,
I was determined to help prevent this disease, evaluate new drugs, and
find effective treatments for Alzheimer’s disease and dementia.”
ATCA’s mission to treat Alzheimer's, dementia, memory loss and brain fog
from Long COVID will reshape healthcare for the aging population.
Alzheimer’s Treatment Centers of America uses Expert Artificial
Intelligence (AI) technology with AI tools to create personalized care
plans aimed at helping physicians improve patient care.
“Alzheimer’s Treatment Centers of America is not a start-up; it is a
roll out and it is ready to scale. There is no more R & D to prove
out. Alpha testing, Beta testing, R & D testing, and Marketing
testing have all been successfully accomplished. ATCA is in-network
with Medicare, Medicaid, Medicare Advantage and all major insurance,”
said CEO Greg Buckley (MBA -Harvard Business School, BSME University of
Michigan).
ABOUT DR. MARK ROSENBLOOM
Mark Rosenbloom MD is the Founder and Chief Medical Officer at LIFEFORCE
Medical Institute. He began his training at McGill University in
Montreal, Canada, completed his MBA at Stanford University, and then
fulfilled his dream to become a physician at Northwestern University
Feinberg School of Medicine where he ranked #1 in clinical sciences.
Dr. Rosenbloom founded PEPID LLC, which is now recognized as the premier
point of care medical/drug and decision support software. Dr.
Rosenbloom founded the Unicorn Children’s Foundation shortly after his
three-year-old son was diagnosed with autism as well as The Boca School
of Autism. He is also a member of Tiger21 where his success can become
more meaningful and impactful with other global entrepreneurs, investors
and executives.
ABOUT ALZHEIMER’S TREATMENT CENTERS OF AMERICA (ATCA)
Alzheimer’s Treatment Centers of America focuses on the multiple root
causes of Alzheimer's and dementia and plans to open its first ATCA
clinic in Atlanta, GA in Q2 2024. There is need for thousands of ATCA
clinics in the USA and tens of thousands of ATCA clinics worldwide.
Alzheimer’s Treatment Centers of America (ATCA) only treats Alzheimer’s
disease, Dementia, Cognitive Impairment and Brain Fog from Long COVID,
using Artificial Intelligence combined with Personalized Precision
Medicine. In the study of its AI protocol, 75% of the patients had no
further decline in their mild cognitive impairment.
No comments:
Post a Comment